Canine atopic dermatitis: systemic immunomodulatory protocol based on clinical phenotype

ABSTRACT: Canine atopic dermatitis (cAD) is a multifactorial allergic disease associated with immune dysfunction and abnormal skin barrier. Several immunological mediators play a role in its pathogenesis. Such molecules are produced by the activation of T helper lymphocytes (Th) through polarization to Th1 and/or Th2, which contributes to different lesion patterns. Acute lesions are mediated by an activation of the Th2 cytokine axis, which clinically induces erythema and pruritus. Conversely, in chronic injuries a mixed immune response of Th1/Th2 cytokines occurs, leading to hyperpigmented and lichenified skin. The clinical understanding of these patterns and the mode of action of immunomodulators are crucial for the best clinical management of the atopic patient. In this context, this review discussed the role of the immune response and the immunomodulatory drugs in dogs with atopic dermatitis and suggested a therapeutic protocol based on clinical phenotype. Based on the evidences showed in this review, it is considered appropriate to use immunomodulatory drugs that target cytokine spectrum related with the clinical phenotype of cAD.

Saved in:
Bibliographic Details
Main Authors: Ferreira,Tiago Cunha, Cunha,Marina Gabriela Monteiro Carvalho Mori da, Nunes-Pinheiro,Diana Célia Sousa
Format: Digital revista
Language:English
Published: Universidade Federal de Santa Maria 2023
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-84782023000800604
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0103-84782023000800604
record_format ojs
spelling oai:scielo:S0103-847820230008006042023-02-07Canine atopic dermatitis: systemic immunomodulatory protocol based on clinical phenotypeFerreira,Tiago CunhaCunha,Marina Gabriela Monteiro Carvalho Mori daNunes-Pinheiro,Diana Célia Sousa canine atopy inflammatory disease immunomodulators ABSTRACT: Canine atopic dermatitis (cAD) is a multifactorial allergic disease associated with immune dysfunction and abnormal skin barrier. Several immunological mediators play a role in its pathogenesis. Such molecules are produced by the activation of T helper lymphocytes (Th) through polarization to Th1 and/or Th2, which contributes to different lesion patterns. Acute lesions are mediated by an activation of the Th2 cytokine axis, which clinically induces erythema and pruritus. Conversely, in chronic injuries a mixed immune response of Th1/Th2 cytokines occurs, leading to hyperpigmented and lichenified skin. The clinical understanding of these patterns and the mode of action of immunomodulators are crucial for the best clinical management of the atopic patient. In this context, this review discussed the role of the immune response and the immunomodulatory drugs in dogs with atopic dermatitis and suggested a therapeutic protocol based on clinical phenotype. Based on the evidences showed in this review, it is considered appropriate to use immunomodulatory drugs that target cytokine spectrum related with the clinical phenotype of cAD.info:eu-repo/semantics/openAccessUniversidade Federal de Santa MariaCiência Rural v.53 n.8 20232023-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-84782023000800604en10.1590/0103-8478cr20220068
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Ferreira,Tiago Cunha
Cunha,Marina Gabriela Monteiro Carvalho Mori da
Nunes-Pinheiro,Diana Célia Sousa
spellingShingle Ferreira,Tiago Cunha
Cunha,Marina Gabriela Monteiro Carvalho Mori da
Nunes-Pinheiro,Diana Célia Sousa
Canine atopic dermatitis: systemic immunomodulatory protocol based on clinical phenotype
author_facet Ferreira,Tiago Cunha
Cunha,Marina Gabriela Monteiro Carvalho Mori da
Nunes-Pinheiro,Diana Célia Sousa
author_sort Ferreira,Tiago Cunha
title Canine atopic dermatitis: systemic immunomodulatory protocol based on clinical phenotype
title_short Canine atopic dermatitis: systemic immunomodulatory protocol based on clinical phenotype
title_full Canine atopic dermatitis: systemic immunomodulatory protocol based on clinical phenotype
title_fullStr Canine atopic dermatitis: systemic immunomodulatory protocol based on clinical phenotype
title_full_unstemmed Canine atopic dermatitis: systemic immunomodulatory protocol based on clinical phenotype
title_sort canine atopic dermatitis: systemic immunomodulatory protocol based on clinical phenotype
description ABSTRACT: Canine atopic dermatitis (cAD) is a multifactorial allergic disease associated with immune dysfunction and abnormal skin barrier. Several immunological mediators play a role in its pathogenesis. Such molecules are produced by the activation of T helper lymphocytes (Th) through polarization to Th1 and/or Th2, which contributes to different lesion patterns. Acute lesions are mediated by an activation of the Th2 cytokine axis, which clinically induces erythema and pruritus. Conversely, in chronic injuries a mixed immune response of Th1/Th2 cytokines occurs, leading to hyperpigmented and lichenified skin. The clinical understanding of these patterns and the mode of action of immunomodulators are crucial for the best clinical management of the atopic patient. In this context, this review discussed the role of the immune response and the immunomodulatory drugs in dogs with atopic dermatitis and suggested a therapeutic protocol based on clinical phenotype. Based on the evidences showed in this review, it is considered appropriate to use immunomodulatory drugs that target cytokine spectrum related with the clinical phenotype of cAD.
publisher Universidade Federal de Santa Maria
publishDate 2023
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-84782023000800604
work_keys_str_mv AT ferreiratiagocunha canineatopicdermatitissystemicimmunomodulatoryprotocolbasedonclinicalphenotype
AT cunhamarinagabrielamonteirocarvalhomorida canineatopicdermatitissystemicimmunomodulatoryprotocolbasedonclinicalphenotype
AT nunespinheirodianaceliasousa canineatopicdermatitissystemicimmunomodulatoryprotocolbasedonclinicalphenotype
_version_ 1758024451847356416